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The receptor tyrosine kinase ErbB2 (HER2) is over-
expressed in multiple human tumors of epithelial origin.
High ErbB2 expression is functionally involved in tumor-
igenesis and correlates with poor clinical prognosis. For
immunotherapy of ErbB2 expressing tumors, we devel-
oped a strategy to supply the tumor cells with costimula-
tory activity. A bispecific fusion protein was constructed
(BIg5), containing the IgV-like domain of huCD86, the
CH2/CH3 domain of huIgG1 and the ErbB2-specific sin-
gle chain antibody fragment scFv(FRP5). A similar fusion
protein lacking the CD86 domain (Ig5) was used as a con-
trol. Upon binding of BIg5 to ErbB2 on tumor cells, these
cells display CD86 on their surface and thus can deliver
costimulatory signals for T-cell activation. In addition, NK
cells could be activated by CD86 binding to CD28. BIg5 is
secreted by eukaryotic cells as a homodimer with
increased stability compared to monomers and possibly
enhanced costimulatory activity due to crosslinking of
CD28 on effector cells. By FACS analysis, specific binding
of the scFv(FRP5) domain to ErbB2 as well as CD86 IgV
binding to CTLA-4 could be demonstrated. Together with
anti-CD3 antibody, BIg5 stimulates proliferation of
human CD2-purified lymphocytes in vitro. After binding
to ErbB2 on murine Renca-lacZ/ErbB2 tumor cells, about
50% of initially bound BIg5 is still present on the cell sur-
face after 4 hours. For delivery of chimeric fusion proteins
in vivo, we used syngeneic, stably transfected HC11 mam-
mary epithelial cells continuously secreting the proteins.
Inoculation of these bystander cells close to subcutane-
ously growing Renca-lacZ/ErbB2 tumors should provide a
long-lasting source to achieve high local concentrations of
BIg5 at the tumor site. In vivo HC11-BIg5 cells proved to
be non-tumorigenic and secreted BIg5 for several weeks,
causing a strong anti-BIg5 antibody response. Treatment
of established Renca-lacZ/ErbB2 or ErbB2-negative Renca-
lacZ tumors by peritumoral inoculation of either HC11-
BIg5 or HC11-Ig5 cells led to rejection of all Renca-lacZ/
ErbB2, but none of the Renca-lacZ tumors. HC11neo con-
trol cells had no effect on tumor growth. Rejection of
ErbB2+ tumors led to long-term protection also against
subsequent challenge with intravenously injected ErbB2-
tumor cells. Intraperitoneal injection of bystander cells
secreting the fusion proteins did not lead to tumor regres-
sion suggesting that high local concentrations at the
tumor site are necessary to target ErbB2 on tumor cells
and to overcome elimination of BIg5 or Ig5 by neutraliz-
ing antibodies. The CD86 IgV domain of BIg5 did not play
a major role in the observed antitumoral immune
response suggesting NK-cell mediated ADCC as the initial
effector mechanism followed by activation of tumor spe-
cific T cells. Targeting of ErbB2 on tumor cells with anti-
body fusion proteins that interact specifically with the
host immune system could be an efficient and specific
approach for therapy of solid ErbB2+ tumors.
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